Alternative signaling: Cardiomyocyte β1-adrenergic receptors signal through EGFRs

Journal of Clinical Investigation

Volumn 117, Issue 9, 2007, Pages 2396-2398

  Engelhardt, Stefan ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; BETA 1 ADRENERGIC RECEPTOR; CYCLIC AMP; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN TYROSINE KINASE;

CELL DEATH; HEART FAILURE; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 34848879491     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33135     Document Type: Review

References (23)

1. Cohn, J.N., et al. 1984. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311:819-823.
2. Bristow, M.R. 2000. β-adrenergic receptor blockade in chronic heart failure. Circulation. 101:558-569.
3. Engelhardt, S. 2005. β-adrenergic receptors in heart failure. Heart Fail. Clin. 1:183-191.
4. Lohse, M.J., Engelhardt, S., and Eschenhagen, T. 2003. What is the role of β-adrenergic signaling in heart failure? Circ. Res. 93:896-906.
5. Bristow, M.R., et al. 1982. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N. Engl. J. Med. 307:205-211.
6. 1-adrenergic receptor in transgenic mice. J. Mol. Cell. Cardiol. 32:817-830.
7. 1-adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 96:7059-7064.
8. Rockman, H.A., Koch, W.J., and Lefkowitz, R.J. 2002. Seven-transmembrane- spanning receptors and heart function. Nature. 415:206-212.
9. Lefkowitz, R.J., Rajagopal, K., and Whalen, E.J. 2006. New roles for β-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol. Cell. 24:643-652.
10. 1- adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 117:2445-2458. doi:10.1172/JCI31901.
11. Daub, H., Weiss, F.U., Wallasch, C., and Ullrich, A. 1996. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 379:557-560.
12. Prenzel, N., et al. 1999. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 402:884-888.
13. Fischer, O.M., Hart, S., Gschwind, A., and Ullrich, A. 2003. EGFR signal transactivation in cancer cells. Biochem. Soc. Trans. 31:1203-1208.
14. 2-adrenergic receptor to different G proteins by protein kinase A. Nature. 390:88-91.
15. 2-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J. Biol. Chem. 275:9572-9580.
16. 2-adrenergic receptor signalling. Cell Signal. 18:1633-1646.
17. Asakura, M., et al. 2002. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 8:35-40.
18. Zhang, H., Chalothorn, D., Jackson, L.F., Lee, D.C., and Faber, J.E. 2004. Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ. Res. 95:989-997.
19. Crone, S.A., et al. 2002. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8:459-465.
20. Slamon, D.J., et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783-792.
21. Ohtsu, H., Dempsey, P.J., and Eguchi, S. 2006. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am. J. Physiol. Cell Physiol. 291:C1-C10.
22. Galandrin, S., and Bouvier, M. 2006. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol. Pharmacol. 70:1575-1584.
23. 1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J. Clin. Invest. 117:229-235. doi:10.1172/JCI30012.